Ciplamedica Pharmaceutical Industri Pharmaceutical Import Profile — Yemen (DGFT 2022–2026)

Name: Ciplamedica Pharmaceutical Industri Pharmaceutical Import Records from India — 5 Products, $2.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ciplamedica Pharmaceutical Industri — Pharmaceutical Importer Profile (2026) | 5 Products, $2.5M Trade | TransData Nexus

Ciplamedica Pharmaceutical Industri

Pharmaceutical Importer · Yemen · Gastrointestinal Focus · $2.5M Total Trade · DGFT Verified

Ciplamedica Pharmaceutical Industri is a pharmaceutical importer based in Yemen with a total trade value of $2.5M across 5 products in 4 therapeutic categories. Based on 56 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ciplamedica Pharmaceutical Industri sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Ciplamedica Pharmaceutical Industri — Import Portfolio & Supplier Network

Ciplamedica Pharmaceutical Industri import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ciplamedica Pharmaceutical Industri?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$6.8M	530	100.0%

Ciplamedica Pharmaceutical Industri sources from 1 verified Indian supplier across 296 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Ciplamedica Pharmaceutical Industri Import?

Formulation	Value	Ships
Urisoda granules sachets (sodium	$372.5K	19
Ciplox 500 tablet (ciprofloxacin 500 MG)	$227.9K	6
Lomac 20 capsules omeprazole 20 MG inv.qty.16400 Pack 30x10s=4920000	$200.0K	4
Parafizz plus eff. tablet (paracetamol	$154.4K	11
Cipril 5 tablets (lisinopril 5 MG) (inv.	$111.5K	12
Lomac 20 capsules (omeprazole 20 MG)	$81.4K	3
Parafizz effervescent tablet	$75.4K	5
Pantosec 40 tablets (pantoprazole sodium) (inv.qty.5472 Pack 10x7s=383040 nos)	$71.3K	2
Lansec 30 capsule ( lansoprazole ) (inv.	$66.3K	2
Dyrade m tablet ( diloxanide furoate	$61.4K	3
Bendex 400 tablet (albendazole 400 MG	$50.0K	1
Valtec cr 500 tablet (sodium valproate	$50.0K	1
Lomac 20 capsules omeprazole 20 MG inv.qty.16420 Pack 30x10s=4926000	$50.0K	1
Lomac 20 capsules omeprazole 20 MG inv.qty.16540 Pack 30 x 10s =4962000	$50.0K	1
Lomac 20 capsules omeprazole 20 MG inv.qty.16412 Pack 30x10s=4923600	$50.0K	1

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Omeprazole	Gastrointestinal	$700.0K	14	0.1%	3
2	Pantoprazole	Gastrointestinal	$700.0K	14	0.1%	11
3	Carvedilol	Cardiovascular	$500.0K	10	0.5%	3
4	Torsemide	Diuretics	$383.3K	12	2.1%	6
5	Salicylic	Combination Drugs	$208.8K	6	1.2%	16

Ciplamedica Pharmaceutical Industri imports 5 pharmaceutical products across 4 categories into Yemen totaling $2.5M.

Ciplamedica Pharmaceutical Industri — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ciplamedica Pharmaceutical Industri is a pharmaceutical importer based in Yemen, specializing in the procurement of finished pharmaceutical formulations. The company is headquartered in Sanaa, Yemen, and operates under the legal name Ciplamedica Pharmaceutical Industri Es Limited. It serves as a key player in Yemen's pharmaceutical distribution network, facilitating the importation and distribution of various pharmaceutical products to meet the country's healthcare needs.

The company's primary supplier is Cipla Limited, a leading Indian pharmaceutical manufacturer. Ciplamedica Pharmaceutical Industri imports a diverse range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, across multiple therapeutic categories. This extensive product portfolio enables the company to address a wide array of medical conditions prevalent in Yemen.

2Distribution Network

Ciplamedica Pharmaceutical Industri's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout Yemen. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's operations are centered in Sanaa, the capital city, which serves as a logistical hub for distribution. The company likely utilizes a combination of regional warehouses and partnerships with local distributors to facilitate nationwide coverage. This approach ensures that pharmaceutical products are accessible to healthcare providers and patients across the country.

3Industry Role

In Yemen's pharmaceutical supply chain, Ciplamedica Pharmaceutical Industri functions primarily as a wholesaler and importer. By sourcing finished pharmaceutical formulations from international manufacturers, particularly from India, the company plays a crucial role in bridging the gap between global pharmaceutical production and local market demand. Its operations are essential for maintaining a steady supply of medications, thereby supporting the healthcare infrastructure in Yemen.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ciplamedica Pharmaceutical Industri

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ciplamedica Pharmaceutical Industri's sourcing strategy exhibits a high degree of concentration, with Cipla Limited being the sole supplier for all imported products. This single-source dependency could pose risks, such as supply chain disruptions or price fluctuations. However, the consistent volume of shipments—56 in total—suggests a stable and long-term relationship between Ciplamedica Pharmaceutical Industri and Cipla Limited. The total import value of $2.5 million USD indicates a significant commitment, which may provide leverage in negotiations and ensure preferential treatment from the supplier.

2Supply Chain Resilience

The resilience of Ciplamedica Pharmaceutical Industri's supply chain is closely tied to its exclusive partnership with Cipla Limited. While this relationship offers stability, it also means that any disruptions at Cipla's end could directly impact Ciplamedica's operations. The company's reliance on a single supplier may limit its ability to diversify sourcing options. Additionally, the lack of publicly available information on backup suppliers and the diversity of formulations imported suggests potential vulnerabilities in the supply chain.

3Strategic Implications

Importing Pharmaceuticals into Yemen — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Yemen

1Regulatory Authority & Framework

Yemen's pharmaceutical sector is regulated by the Ministry of Public Health and Population, which oversees the importation, registration, and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Customs Law No. 14 of 1990 and its amendments, which outline the procedures and requirements for importing goods into Yemen. The Ministry is responsible for ensuring that imported pharmaceuticals meet the country's health and safety standards.

2Import Licensing & GMP

To import pharmaceutical products into Yemen, companies must obtain an import license from the Ministry of Public Health and Population. This process involves registering the company with the Ministry and ensuring compliance with all regulatory requirements. Yemen recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers are required to ensure that their suppliers hold valid GMP certifications to guarantee the quality and safety of imported pharmaceuticals.

3Quality & Labeling

Ciplamedica Pharmaceutical Industri — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ciplamedica Pharmaceutical Industri's focus on gastrointestinal, cardiovascular, and diuretic medications aligns with the prevalent health concerns in Yemen. The high import values of omeprazole and pantoprazole, both proton pump inhibitors used to treat gastrointestinal disorders, indicate a significant demand for such treatments. Similarly, the substantial imports of carvedilol, a beta-blocker for cardiovascular conditions, and torsemide, a diuretic, reflect the company's strategic emphasis on addressing chronic health issues common in the region.

2Sourcing Profile

Ciplamedica Pharmaceutical Industri's sourcing strategy is centered on importing generic pharmaceutical formulations from India, primarily from Cipla Limited. This approach allows the company to offer cost-effective medications while maintaining a diverse product portfolio. The focus on finished formulations, rather than raw active pharmaceutical ingredients (APIs), suggests a streamlined supply chain and a commitment to delivering ready-to-use products to the Yemeni market.

3Market Positioning

By importing a wide range of pharmaceutical products, Ciplamedica Pharmaceutical Industri serves multiple segments of the Yemeni market, including retail pharmacies, hospitals, and government tenders. The company's extensive product portfolio enables it to meet the diverse needs of healthcare providers and patients, positioning it as a comprehensive supplier in Yemen's pharmaceutical distribution network.

Seller's Guide — How to Become a Supplier to Ciplamedica Pharmaceutical Industri

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Yemeni market by partnering with Ciplamedica Pharmaceutical Industri. The company's exclusive relationship with Cipla Limited indicates a preference for established manufacturers, which could facilitate the introduction of additional suppliers. Potential gaps in Ciplamedica's current sourcing include specific therapeutic areas or product forms not currently covered, presenting opportunities for new suppliers to meet these unmet needs.

2Requirements & Qualifications

Indian exporters seeking to supply Ciplamedica Pharmaceutical Industri must ensure that their products are registered with the Ministry of Public Health and Population in Yemen. They must also hold valid GMP certifications recognized by international bodies such as WHO or PIC/S. Compliance with Yemeni labeling requirements, including Arabic language labeling, is mandatory. Additionally, obtaining a Certificate of Pharmaceutical Products (COPP) from the relevant Indian authorities is essential for the import authorization process.

3How to Approach

Frequently Asked Questions — Ciplamedica Pharmaceutical Industri

What products does Ciplamedica Pharmaceutical Industri import from India?

Ciplamedica Pharmaceutical Industri imports 5 pharmaceutical products across 4 categories. Top imports: Omeprazole ($700.0K), Pantoprazole ($700.0K), Carvedilol ($500.0K), Torsemide ($383.3K), Salicylic ($208.8K).

Who supplies pharmaceuticals to Ciplamedica Pharmaceutical Industri from India?

Ciplamedica Pharmaceutical Industri sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $6.8M).

What is Ciplamedica Pharmaceutical Industri's total pharmaceutical import value?

Ciplamedica Pharmaceutical Industri's total pharmaceutical import value from India is $2.5M, based on 56 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ciplamedica Pharmaceutical Industri focus on?

Ciplamedica Pharmaceutical Industri imports across 4 categories. The largest: Gastrointestinal (56.2%), Cardiovascular (20.1%), Diuretics (15.4%).

Get Full Ciplamedica Pharmaceutical Industri Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.